Biodesix (BDSX) Change in Accured Expenses (2019 - 2026)

Biodesix has reported Change in Accured Expenses for 8 years, with the latest figure at -$2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 20.95% year-over-year to -$2.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (up 55.73% YoY), and the FY2025 full-year result was $1.9 million, up 13.56% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$2.3 million, down from $974000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $3.3 million in Q2 2023, with the low at -$2.3 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $52470.6 across 5 years, with a median of $486000.0 in 2025.
• The largest YoY upside for Change in Accured Expenses was 2897.25% in 2023 against a maximum downside of 370.13% in 2023.
• Biodesix's Change in Accured Expenses stood at -$127000.0 in 2022, then jumped by 698.43% to $760000.0 in 2023, then jumped by 122.89% to $1.7 million in 2024, then sank by 42.5% to $974000.0 in 2025, then plunged by 340.66% to -$2.3 million in 2026.
• The last three Change in Accured Expenses figures came in at -$2.3 million (Q1 2026), $974000.0 (Q4 2025), and $486000.0 (Q3 2025), per Business Quant data.